Montalbano Marzia, Piccolo Paola, Lionetti Raffaella, Visco-Comandini Ubaldo, Agrati Chiara, Grassi Germana, Meschi Silvia, Matusali Giulia, Conte Federica, Angelone Federica, Ettorre Giuseppe Maria, Guglielmo Nicola, Maggi Fabrizio, Francalancia Massimo, Mereu Tiziana, Puro Vincenzo, Girardi Enrico, D'Offizi Gianpiero
National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy.
Internal Medicine, Fatebenefratelli Hospital Isola Tiberina Gemelli Isola, Rome, Italy.
Liver Int. 2023 May;43(5):1120-1125. doi: 10.1111/liv.15557. Epub 2023 Apr 1.
Weaker responses have been described after two doses of anti-SARS-CoV2 vaccination in liver transplant recipients (LTRs). At the Italian National Institute for Infectious Diseases, 122 LTRs (84% males, median age 64 years) were tested for humoral and cell-mediated immune response after a third doses of anti-SARS-CoV2 mRNA vaccines. Humoral response was measured by quantifying anti-receptor binding domain and neutralizing antibodies; cell-mediated response was measured by quantifying IFN-γ after stimulation of T cells with SARS-CoV-2-specific peptides. Humoral and cellular responses improved significantly compared to the second vaccine dose; 86.4% of previous non-responders to the first 2 vaccine doses (N = 22) became responders. Mycophenolate mofetil-containing regimens were not associated with lower response rates to a third vaccine; shorter time since transplantation (<6 years) was associated with lower humoral and cellular responses to third vaccine. Protective antibodies against Omicron variant were detected in 60% of patients 12 weeks after third vaccine dose.
肝移植受者（LTRs）接种两剂抗SARS-CoV2疫苗后反应较弱。在意大利国家传染病研究所，122名LTRs（84%为男性，中位年龄64岁）在接种第三剂抗SARS-CoV2 mRNA疫苗后接受了体液和细胞介导免疫反应检测。通过定量抗受体结合域和中和抗体来测量体液反应；通过用SARS-CoV-2特异性肽刺激T细胞后定量IFN-γ来测量细胞介导反应。与第二剂疫苗相比，体液和细胞反应显著改善；之前对前两剂疫苗无反应的人群中，86.4%（N = 22）变为有反应者。含霉酚酸酯的方案与第三剂疫苗的较低反应率无关；移植后时间较短（<6年）与对第三剂疫苗的较低体液和细胞反应有关。第三剂疫苗接种12周后，60%的患者检测到针对奥密克戎变体的保护性抗体。
